The director overseeing investigations of potential advertising breaches at the Therapeutic Goods Administration (TGA) expressed concern about the “high level of non-compliance” in the medicinal cannabis industry, particularly related to promotion not endorsed by the TGA and use of patient testimonials. Despite a slowdown in enforcement actions, the TGA plans to hold senior industry executives accountable.
Read the full story here
Written by: Steve Jones
Published on March 14, 2024 at 10:37AM
Source: Cannabiz (opens in new tab)